Siemens rolls out new PET/CT system, highlights disease-specific imaging

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Siemens this week added the new TruePoint technology to its Biograph family of hybrid PET/CT systems. The TruePoint PET/CT platform adds 33 percent more axial volume coverage to Siemens PET/CT scanners as well as cutting in half the patient injected dose of radiopharmaceuticals, the company said.

“Benefits provided by the new TruePoint PET/CT platform are two-fold – the technology increases the axial coverage per bed position to provide whole-body PET/CT protocols, while optimizing workflow by using fewer bed positions and increased speed,” said Michael Reitermann, president, Molecular Imaging Division, Siemens Medical Solutions. “TruePoint PET/CT also provides a new level of system integration for PET/CT technology and software applications that maximize efficiency and improve diagnostic confidence.”

Enlarging the PET field of view, TruePoint PET/CT technology is able to detect 78 percent more photons by automatically adjusting reconstruction and scatter correction algorithms to individual patient size. Along with enhanced speed, TruePoint offers the most advanced, clinically proven scatter correction techniques on the market, Siemens said.

Workflow optimization is achieved by using fewer bed positions for exams, which helps to increase patient comfort and decrease patient movement. This results in shorter scan times and higher quality images. 

“The addition of the TruePoint PET•CT platform to our Biograph family will advance patient care, as the system can improve the ability to diagnose with more accuracy and treat disease states earlier, while its shorter scan times provide increased patient comfort,” said Reitermann. “The technology enables Siemens to deliver a highly effective scanning method that meets molecular imaging requirements of today and tomorrow.”

Siemens this week also highlighted molecular imaging solutions suited for a variety of environments, such as:

  • Oncology _ Hybrid imaging solutions such as the Biograph family of PET/CT systems and the Symbia family of SPECT/CT scanners and software suites such as the syngo MultiModality Workplace, which offers intuitive post processing and advanced visualization. syngo TrueD is a tool that enables physicians to quickly co-register and compare patient scans from different points in time, such as pre- and post-therapy.

  • Cardiology _ Siemens highlighted its cardiology solutions, including c.cam, e.cam, Symbia SPECT, Symbia SPECT/CT, and Biograph PET/CT systems. New workflow enhancements to the Symbia line of hybrid imagers include automatic and integrated collimator changing options, as well as an automatic quality control option that automates all daily, weekly and monthly quality control needs of the system. Siemens Biograph 64 with the new TruePoint PET/CT technology package performs high-resolution CT angiography and myocardial perfusion and viability in a single exam. The company also highlighted its syngo CardioFusion software for coronary anatomy and calcium scoring on 3D volumes with hybrid imaging.
  • Neurology _ In addition to hybrid technologies, which are gaining momentum in the neurological environment, sophisticated computer-aided brain function analysis tools such as syngo Scenium facilitate neurological evaluation by enabling automatic correlation of a patient study with an average brain for assessment of abnormalities. Other advancements include imaging biomarkers that will help physicians detect both ß-amyloid plaques and neuronal tangles to predict the onset of dementia and neurological disorders – often before symptoms appear.
  • Preclinical Imaging _ Siemens’ preclinical, multimodality imaging solutions offer a versatile and upgradeable platform as well as a comprehensive suite of analysis applications. Siemens’ newest preclinical solution, Inveon, is a modular concept that offers complete flexibility, enabling PET, SPECT, and CT data acquisition, and provides the industry’s highest PET resolution and sensitivity. Inveon’s suite of research tools can help facilitate basic research, as well as the drug development process, empowering researchers to identify specific biological processes, monitor the efficacy of compounds, and measure the effects of disease progression over time.
  • Advanced Services _ Siemens Molecular Imaging (MI) University, a fundamental part of MI LifeNet, Siemens’ customer care initiative, provides a substantive training resource for Siemens’ customers as well as referring physician for